US 11,896,583 B2
Tinostamustine for use in treating ovarian cancer
Thomas Jorg Mehrling, Basel (CH)
Assigned to Purdue Pharma L.P., Stamford, CT (US)
Appl. No. 16/621,893
Filed by EURO-CELTIQUE S.A., Luxembourg (LU)
PCT Filed Jun. 13, 2018, PCT No. PCT/EP2018/065669
§ 371(c)(1), (2) Date Dec. 12, 2019,
PCT Pub. No. WO2018/229134, PCT Pub. Date Dec. 20, 2018.
Claims priority of application No. 1709405 (GB), filed on Jun. 13, 2017.
Prior Publication US 2020/0261423 A1, Aug. 20, 2020
Int. Cl. A61K 31/4184 (2006.01); A61P 35/00 (2006.01); A61K 33/243 (2019.01); A61K 31/337 (2006.01)
CPC A61K 31/4184 (2013.01) [A61K 31/337 (2013.01); A61K 33/243 (2019.01); A61P 35/00 (2018.01)] 14 Claims
 
1. A method of treating ovarian cancer in a patient in need thereof, comprising administering to said patient an effective amount of tinostamustine or a pharmaceutically acceptable salt thereof, and carboplatin;
wherein tinostamustine or pharmaceutically acceptable salt thereof is administered at a dosage level of from 60 to 150 mg/m2 body surface area of the patient; and,
wherein the tinostamustine or pharmaceutically acceptable salt thereof is administered intravenously to the patient in need thereof on days 1, 8 and 15 of a 28-day treatment cycle.